Table 1.
Patient characteristics.
| Characteristic | n = 52 |
|---|---|
| Median age (range), years | 40 (19-78) |
| Sex | |
| Female | 31 (60%) |
| Male | 21 (40%) |
| ECOG performance status | |
| 0-1 | 36 (69.3%) |
| ≥2 | 4 (7.6%) |
| NA | 12 (23.1%) |
| IMDC prognostic group | |
| Favorable | 9 (17.3%) |
| Intermediate | 35 (67.3%) |
| Poor | 8 (15.4%) |
| Previous nephrectomy | 37 (71%) |
| Stage at diagnosis | |
| I–IIII | 27 (52%) |
| IV | 25 (48%) |
| Cabozantinib line | |
| 1 | 11 (21.2%) |
| 2 | 15 (28.8%) |
| >2 | 26 (50%) |
| FISH | |
| Positive | 40 (77%) |
| Not available | 12 (23%) |
| Translocation | |
| TFE3 | 46 (88.5%) |
| TFEB | 6 (11.5%) |
| Metastatic sites | |
| Retroperitoneal lymph nodes | 27 (52%) |
| Mediastinal lymph nodes | 17 (32.7%) |
| Lung | 28 (53.8%) |
| Bone | 22 (42.3%) |
| Liver | 18 (34.6%) |
| Brain | 4 (7.7%) |
| Nature of prior systemic therapies, (n = 41) | |
| VEGF TKI monotherapy | 33 (80%) |
| Immune checkpoint inhibitor monotherapy | 20 (49%) |
| Combination ICI and VEGF TKI | 6 (14.6%) |
| Combination ICI | 7 (17%) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; FISH, florescent in situ hybridization; TKI, tyrosine kinase inhibitors; ICI, immune checkpoint inhibit; VEGF, vascular endothelial growth factor.